Measurement of Dabigatran Concentration Using Finger Prick Dried Blood Spot Sample Collection
Frontiers in Pharmacology, 2021 Background and Purpose: Real-world laboratory monitoring of dabigatran activity is challenging. The purpose of the present study was to demonstrate the feasibility and accuracy of finger prick sampling with dried blood spot (fpDBS) cards in measuring the
Shin-Yi Lin +7 more
doaj +1 more source
Global Thrombosis Test - a possible monitoring system for the effects and safety of dabigatran [PDF]
, 2015 © Otsui et al. 2015BACKGROUND: Dabigatran is an alternative to warfarin (WF) for the thromboprophylaxis of stroke in patients with non-valvular atrial fibrillation (NVAF). The advantage of dabigatran over WF is that monitoring is not required; however, a
Gorog, Diana A +8 more
core +1 more source
Evidence supporting idarucizumab for the reversal of dabigatran. [PDF]
, 2016 Idarucizumab is a monoclonal antibody fragment specifically targeted to dabigatran. It has demonstrated prompt and durable reversal of the anticoagulant effects of dabigatran in animal studies and phase 1 studies of young, elderly, and renally impaired ...
Pollack, Charles V.
core +2 more sources
Journal of Arrhythmia, 2015 Background: Activated partial thromboplastin time (aPTT) is recommended for monitoring anticoagulant activity in dabigatran-treated patients; however, there are limited data in Japanese patients.
Daiki Shimomura +14 more
doaj +1 more source
GRADE Evidence to Decision (EtD) frameworks : a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines [PDF]
, 2016 Funding: Work on this article has been partially funded by the European Commission FP7 Program (grant agreement 258583) as part of the DECIDE project. Sole responsibility lies with the authors; the European Commission is not responsible for any use that ...
the GRADE Working Group
core +1 more source
Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases. [PDF]
, 2020 OBJECTIVE: The evolution of non-vitamin K antagonist anticoagulants (NOACs) has changed the horizon of stroke prevention in atrial fibrillation (SPAF).
Acar, RD +12 more
core +1 more source
Bleeding with direct oral anticoagulants vs warfarin: clinical experience. [PDF]
, 2016 The risk of bleeding in the setting of anticoagulant therapy continues to be re-evaluated following the introduction of a new generation of direct oral anticoagulants (DOACs).
Eikelboom, John, Merli, Geno J.
core +2 more sources
Thrombolysis in a stroke patient on dabigatran anticoagulation: case report and synopsis of published cases [PDF]
, 2013 We present the case of an aphasic 77-year-old stroke patient with left distal M1 occlusion who received rt-PA for thrombolysis while on oral anticoagulant treatment with dabigatran (150 mg b.i.d.).
Abruscato, Mario Giovanni Rosario +3 more
core +2 more sources
Thrombocytopenia induced by dabigatran: two case reports
BMC Neurology, 2017 Background Vitamin K inhibitors (e.g. warfarin) and indirect thrombin inhibitors (e.g. heparin) are widely used to prevent thromboembolic disorders (e.g. myocardial infarction, venous thromboembolism, and stroke).
Hyun Goo Kang +3 more
doaj +1 more source
How we treat bleeding associated with direct oral anticoagulants [PDF]
, 2016 Direct oral anticoagulants are at least as effective as vitamin K antagonists for the prevention and treatment of thromboembolism. Unfortunately, differently from vitamin K antagonists, they have the great drawback of lacking specific antidotes in the ...
Franchini, Massimo +4 more
core +1 more source